Two Sigma Advisers LP acquired a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,100 shares of the company's stock, valued at approximately $940,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Quadrant Capital Group LLC lifted its position in Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after buying an additional 511 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Privia Health Group by 8.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company's stock worth $140,000 after buying an additional 533 shares during the last quarter. First Horizon Advisors Inc. lifted its position in Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after buying an additional 632 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in Privia Health Group by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 10,673 shares of the company's stock worth $209,000 after buying an additional 678 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its position in Privia Health Group by 1.5% in the 4th quarter. WINTON GROUP Ltd now owns 60,607 shares of the company's stock worth $1,185,000 after buying an additional 902 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.
Insider Buying and Selling
In related news, CEO Parth Mehrotra sold 15,100 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $352,283.00. Following the sale, the chief executive officer now directly owns 454,281 shares of the company's stock, valued at $10,598,375.73. This represents a 3.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO David Mountcastle sold 3,445 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $80,371.85. Following the completion of the sale, the chief financial officer now directly owns 176,231 shares in the company, valued at approximately $4,111,469.23. The trade was a 1.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,579 shares of company stock valued at $1,226,367 over the last ninety days. Company insiders own 10.70% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on PRVA shares. Barclays boosted their target price on Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Tuesday, May 27th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. JMP Securities reiterated a "market outperform" rating and issued a $29.00 price objective on shares of Privia Health Group in a research report on Monday, April 28th. Truist Financial boosted their price objective on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group boosted their price objective on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Privia Health Group presently has an average rating of "Buy" and a consensus price target of $27.77.
Check Out Our Latest Stock Analysis on PRVA
Privia Health Group Stock Down 0.9%
Shares of PRVA traded down $0.21 during mid-day trading on Thursday, hitting $22.80. 701,290 shares of the company's stock traded hands, compared to its average volume of 739,316. Privia Health Group, Inc. has a 1 year low of $16.37 and a 1 year high of $26.09. The firm has a market capitalization of $2.78 billion, a P/E ratio of 228.02, a PEG ratio of 3.47 and a beta of 0.83. The business's 50-day moving average price is $23.36 and its 200-day moving average price is $22.76.
Privia Health Group Company Profile
(
Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Featured Articles
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
